Tags

Type your tag names separated by a space and hit enter

Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.
J Neurosci. 2009 Feb 18; 29(7):1977-86.JN

Abstract

The accumulation of amyloid-beta (Abeta) peptides in the brain of patients with Alzheimer's disease (AD) may arise from an imbalance between Abeta production and clearance. Overexpression of the Abeta-degrading enzyme neprilysin in brains of human amyloid precursor protein (hAPP) transgenic mice decreases overall Abeta levels and amyloid plaque burdens. Because AD-related synaptic and cognitive deficits appear to be more closely related to Abeta oligomers than to plaques, it is important to determine whether increased neprilysin activity also diminishes the levels of pathogenic Abeta oligomers and related neuronal deficits in vivo. To address this question, we crossed hAPP transgenic mice with neprilysin transgenic mice and analyzed their offspring. Neprilysin overexpression reduced soluble Abeta levels by 50% and effectively prevented early Abeta deposition in the neocortex and hippocampus. However, it did not reduce levels of Abeta trimers and Abeta*56 or improve deficits in spatial learning and memory. The differential effect of neprilysin on plaques and oligomers suggests that neprilysin-dependent degradation of Abeta affects plaques more than oligomers and that these structures may form through distinct assembly mechanisms. Neprilysin's inability to prevent learning and memory deficits in hAPP mice may be related to its inability to reduce pathogenic Abeta oligomers. Reduction of Abeta oligomers will likely be required for anti-Abeta treatments to improve cognitive functions.

Authors+Show Affiliations

Gladstone Institute of Neurological Disease, University of California, San Francisco, California 94158, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

19228952

Citation

Meilandt, William J., et al. "Neprilysin Overexpression Inhibits Plaque Formation but Fails to Reduce Pathogenic Abeta Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice." The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, vol. 29, no. 7, 2009, pp. 1977-86.
Meilandt WJ, Cisse M, Ho K, et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009;29(7):1977-86.
Meilandt, W. J., Cisse, M., Ho, K., Wu, T., Esposito, L. A., Scearce-Levie, K., Cheng, I. H., Yu, G. Q., & Mucke, L. (2009). Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 29(7), 1977-86. https://doi.org/10.1523/JNEUROSCI.2984-08.2009
Meilandt WJ, et al. Neprilysin Overexpression Inhibits Plaque Formation but Fails to Reduce Pathogenic Abeta Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice. J Neurosci. 2009 Feb 18;29(7):1977-86. PubMed PMID: 19228952.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. AU - Meilandt,William J, AU - Cisse,Moustapha, AU - Ho,Kaitlyn, AU - Wu,Tiffany, AU - Esposito,Luke A, AU - Scearce-Levie,Kimberly, AU - Cheng,Irene H, AU - Yu,Gui-Qiu, AU - Mucke,Lennart, PY - 2009/2/21/entrez PY - 2009/2/21/pubmed PY - 2009/4/17/medline SP - 1977 EP - 86 JF - The Journal of neuroscience : the official journal of the Society for Neuroscience JO - J. Neurosci. VL - 29 IS - 7 N2 - The accumulation of amyloid-beta (Abeta) peptides in the brain of patients with Alzheimer's disease (AD) may arise from an imbalance between Abeta production and clearance. Overexpression of the Abeta-degrading enzyme neprilysin in brains of human amyloid precursor protein (hAPP) transgenic mice decreases overall Abeta levels and amyloid plaque burdens. Because AD-related synaptic and cognitive deficits appear to be more closely related to Abeta oligomers than to plaques, it is important to determine whether increased neprilysin activity also diminishes the levels of pathogenic Abeta oligomers and related neuronal deficits in vivo. To address this question, we crossed hAPP transgenic mice with neprilysin transgenic mice and analyzed their offspring. Neprilysin overexpression reduced soluble Abeta levels by 50% and effectively prevented early Abeta deposition in the neocortex and hippocampus. However, it did not reduce levels of Abeta trimers and Abeta*56 or improve deficits in spatial learning and memory. The differential effect of neprilysin on plaques and oligomers suggests that neprilysin-dependent degradation of Abeta affects plaques more than oligomers and that these structures may form through distinct assembly mechanisms. Neprilysin's inability to prevent learning and memory deficits in hAPP mice may be related to its inability to reduce pathogenic Abeta oligomers. Reduction of Abeta oligomers will likely be required for anti-Abeta treatments to improve cognitive functions. SN - 1529-2401 UR - https://www.unboundmedicine.com/medline/citation/19228952/Neprilysin_overexpression_inhibits_plaque_formation_but_fails_to_reduce_pathogenic_Abeta_oligomers_and_associated_cognitive_deficits_in_human_amyloid_precursor_protein_transgenic_mice_ L2 - http://www.jneurosci.org/cgi/pmidlookup?view=long&pmid=19228952 DB - PRIME DP - Unbound Medicine ER -